Objective Hepatitis C is a major cause of liver disease in European countries. We aimed to assess the current and future disease burden of hepatitis C.
Introduction
Infection with the hepatitis C virus (HCV) becomes chronic in 80% of cases [1, 2] , with a 10±20% risk of developing cirrhosis over 20 years [2±5] . Once established, cirrhosis carries a 4% annual risk of decompensation [4] and a 1±5% annual risk of developing hepatocellular cancer (HCC) [6] . Thus, patients infected for 20±30 years have had the HCV infection for suf®cient duration to now be at risk for complications from chronic liver disease including HCC.
Because HCV was not identi®ed until 1988 [7] , few studies have a suf®ciently long follow-up to reliably assess the lifetime consequences of chronic HCV infection [2, 8, 9] . Nonetheless, in selected populations (limiting the generalizability of these studies), signi®cant HCV-related mortality was observed [2, 8] . Recently, when compared with an age-matched and sex-matched general population, the life expectancy of patients with chronic hepatitis C has been shown to be decreased, with the cirrhotic stage accounting fully for the excess mortality [10] .
In Switzerland, reporting of positive tests for hepatitis has been mandatory since 1988 [11] . Since the availability of tests for hepatitis C in late 1988, all registered medical laboratories have to report any positive anti-HCV serology or HCV-RNA polymerase chain reaction to the Swiss Federal Of®ce of Public Health (BAG). To avoid duplicate reporting, each report is crosschecked with the existing database to determine whether the patient has been registered previously. For any newly reported HCV cases, the BAG requests further complementary clinical and epidemiological information from the patient's primary care physician. These data provide insight into changes in the epidemiology of the route of transmission and assist with differentiating acute from chronic hepatitis C. Collec-tively, this dataset creates a unique opportunity to perform epidemiological studies of HCV in Switzerland.
To predict future epidemiological and clinical developments in the midst of uncertainty, modelling techniques have proven useful. Bennett et al. [12] published a Markov model to estimate the morbidity, mortality and costs associated with chronic HCV in the USA. Using a Markov model to back-calculate the hepatitis C epidemic in France, Deuf®c et al. predicted a 33±100% increase in HCC mortality from HCV infection in the next 30 years [13] . Similarly, Wong et al. [14] predicted a twofold increase in mortality related to HCV infection in the USA over the next 10±20 years.
We sought to examine the hepatitis C epidemic in Switzerland by estimating the current prevalence and predicting future HCV-related morbidity, mortality and economic burden. In contrast to the aforementioned modelling studies, by applying the BAG's representative epidemiological database for hepatitis C in Switzerland, we could account not only for prevalence, but also for incidence, thus enabling the development of a comprehensive model.
Methods
Using standard decision analysis software (Decision Maker, Version 7, Division of Clinical Decision Making, New England Medical Center, Boston, USA) [15] , we applied a previously published and validated computer simulation model for the natural history of HCV [12, 16] . The model is based on a Markov simulation, in which cohorts of patients move through prede®ned health states over time until all patients have entered the dead state. The health states include mild hepatitis, moderate hepatitis and cirrhosis as the three histopathological stages. The likelihood that patients may progress to more advanced disease states or death over time was speci®ed by transition probabilities derived from the literature. Time is represented by annual cycles. The model considers morbidity and mortality from hepatitis C and mortality from other causes as occurring in the general Swiss population.
Prevalence
As in other countries, the BAG used the anti-HCV prevalence in blood donors and pregnant women to estimate the prevalence of hepatitis C at 0.5±1% in the 1998 Swiss population, translating into 35 000±70 000 persons who were HCV infected in 1998 [17] . When applied in the United States, prevalence estimates based on a similar approach underestimated the prevalence actually observed when screening was applied to a representative sample of the US population [18, 19] . In the absence of such a population-based seroprevalence study in Switzerland, we attempted to compute the prevalence of HCV infection in Switzerland using simulation techniques.
From the BAG data, we assumed in a ®rst scenario an anti-HCV prevalence of 0.75% (median BAG estimate) and assumed that the age distribution of all`non-acute' hepatitis C cases (Table 1) applied to the entire HCVinfected Swiss population. As found in the NHANES III study [19] , we assumed that 73.9% of those positive for HCV antibody had HCV RNA detectable in their blood so that 38 797 Swiss subjects have chronic HCV RNA positive infection. To estimate the age-speci®c prevalence of cirrhosis in this Swiss population, we used a previously published linear relationship between HCC-related cirrhosis and age (R 2 0.97) in a data set of 2235 liver biopsies [14, 20] . The age-speci®c prevalences of moderate and mild hepatitis were backcalculated from the age-speci®c prevalence of cirrhosis, assuming a 7.3% annual probability of developing cirrhosis from moderate hepatitis [12] . About 30±40% of all chronically infected patients have persistently normal liver transaminases for more than 12 months [21] . We assumed that these patients would not develop progressive liver disease. Many of these patients may still have histological hepatitis [21] . Thus, our results may underestimate future morbidity and mortality from hepatitis C.
Incidence
Since 1993, about 60 cases of acute hepatitis C have been consistently documented annually [22] . Assuming that symptomatic acute hepatitis C occurs in only 10± 20% of those infected, the BAG estimates an annual incidence of seven to 14 new HCV infections per 100 000 inhabitants or 497±995 new infections per year in Switzerland [22] . In the base case, we assumed that 746 newly infected patients would occur per year, i.e. the median of the BAG's estimated range. We assumed that the age distribution of future newly HCV-infected cases in Switzerland would be identical to the age distribution of all cases of acute hepatitis C reported to the BAG between 1992 and 1998 ( Table 2 ). In these newly infected patients, 80% will develop chronic infection [21] .
Extension of the model
To represent treatment patterns within Switzerland, we modi®ed the published hepatitis C model to include the possibility of partial hepatectomy or orthotopic liver transplantation (OLT) for surgically treatable small HCC. The likelihood of, risks of and survival after OLT and partial hepatectomy were based on literature (Medline search) and expert opinion, and are detailed in the Appendix and Figure. 1 and Table 3 .
OLT for HCV-associated end-stage liver disease
Because 27% of OLTs (all indications) at the University Hospital Zu È rich were for HCV-related end-stage liver disease (without HCC) in a consecutive series (E. L. Renner, unpublished data 1997), we assumed that 16 (range, 14±18) of the 60 OLTs being performed in Switzerland in 1994 for non-HCC-related causes were for HCV-related liver disease. In the USA, 730 OLTs were performed for HCV-related liver disease in 1994 [44] , translating to a rate of 2.74 OLTs for HCV-related liver disease per million inhabitants (USA population in 1994, 266 600 000 [45] ). This rate was 2.33 in 1994 for Switzerland (population in 1994, 7 062 400 [46] ). Thus, the overall annual probability of OLT for HCV-related liver disease seems similar (population based) in the USA and Switzerland, differing only by about 15% (not considering alternative assumptions regarding the prevalence of hepatitis C).
Death from liver disease
In 1994, 644 subjects died from chronic liver disease in Switzerland [Swiss Federal Of®ce of Statistics (BFS), unpublished data 1999]. The proportion of these deaths related to HCV infection, however, is unknown. Due to imprecise and incomplete coding by the reporting physicians, cases registered by the BFS (®ve deaths caused by chronic hepatitis C, 59 deaths caused by HBV-related or HCV-related cirrhosis; BFS, unpublished data 1999) are not only very likely to underestimate, but do even not allow one to reliably determine, the fraction of deaths attributable to HCVrelated cirrhosis. In a seroprevalence study on 253 unselected patients with cirrhosis treated in a Swiss general hospital, 17% of cirrhotics (excluding HCC cases) were found to be positive for anti-HCV [35] . Re¯ecting referral patterns, alcoholic cirrhosis may be over-represented in this series, thus leading to underestimation of the fraction of HCV-related liver disease. Of all OLTs performed for end-stage chronic liver disease (excluding other indications such as HCC, metabolic disorders and fulminant liver failures) in a recent series of consecutive OLTs at the University Hospital Zu È rich, 44% were performed for HCV-related end-stage liver disease (E. L. Renner, unpublished data 2000). This latter ®gure, however, probably overestimates the true fraction of deaths attributable to HCVrelated cirrhosis, since among OLT candidates alcoholic cirrhosis is likely to be under-represented. Based on the aforementioned, we therefore assume the pro- Table 2 Age distribution of a cohort (base-case scenario) of antihepatitis C virus (HCV)-positive patients (reported as acute infected) (incidence) portion of deaths from chronic liver disease related to HCV to range between 17 and 44%, which extrapolates to 109±283 deaths in 1994. This compares with an estimate of 40% for the USA [47] .
Effect of antiviral treatment
To approximate the effects of antiviral therapies (i.e. the interferon/ribavirin combination) on our results, we estimated a percentage of 14% with known hepatitis C (15 069 documented patients with anti-HCV positivity [17] out of an assumed 105 000 anti-HCV-positive patients). To consider the effect of these therapies, we assumed that all non-cirrhotic patients with known HCV infection would have been treated, except those with normal transaminases and those with HCC. We applied the age distribution of chronic infected HCV patients (Table 1) and calculated with a sustained response rate to antiviral treatment of 40% [48, 49] .
Costs
Costs were calculated using a societal perspective, and included direct and indirect costs. The present value of future costs applied a 3% annual discount rate [50] .
Direct costs ( the 1998 Swiss Hospital Institute data for OLT [53] to re¯ect the current shortened length of stay [52] and the expanded costs for hospital care [46] . Cost data are similar to those in the United States [54] We assumed that asymptomatic patients with unknown disease would not incur additional health costs until the occurrence of decompensated cirrhosis or HCC.
Indirect costs
Indirect costs were evaluated using the human capital approach [55] . To provide a conservative estimate of indirect costs, we only assumed permanent disability for patients with decompensated cirrhosis or HCC.
Results

Prevalence of hepatitis C in Switzerland
To estimate the prevalence of HCV infection in Switzerland, we compared model predictions regarding the incidence of death from HCV-related HCC and chronic liver disease, and that of HCV-related OLT, with the same events presumably having occurred in 1998 (Table 5 ). Applying the median 0.75% BAG HCV prevalence estimate resulted in outcome predictions that fell below outcome assumptions for HCC and OLT, while the model prediction for deaths from HCV-related chronic liver disease (107 deaths) was at the lower limit of the assumed range (109±283 deaths). According to our model's estimates, 1.25±1.75% of anti-HCV prevalence provided the best ®t to the assumed HCV complications.
Disease burden by prevalence
In the absence of population-based seroprevalence data for Switzerland, we assumed an anti-HCV prevalence of 1.5% (see earlier) in our analyses to predict future HCV-related disease burden. Thus, we examined future complications for a cohort of 77 595 HCV-RNApositive subjects exhibiting an age distribution identical to that of the chronically HCV-infected patients reported to the BAG (Table 6 ). Excluding new HCV infections (i.e. future incidence), the analysis suggests that annual HCC incidence and HCV-related mortality (i.e. death from decompensated cirrhosis and death from liver disease) will increase by 70 and 90%, respectively, reaching their maxima in about 15± 25 years from now. By excluding any future new HCV infections, the incidence of HCV-related cirrhosis would decline rapidly after 2005 (Fig. 2) .
Disease burden by prevalence and future incidence
Calculating with an annual 746 future new HCV infections according to BAG estimates, this analysis considers both, existing HCV infections (prevalence) and new infections (incidence), and permits a simulation of the entire HCV epidemic in Switzerland ( Table  7 ). The simulation was limited up to 2015, since projecting future incidence rates more than 15 years into the future seems to carry a too high uncertainty. Projected HCV-related complications increased only slightly compared with the prior analysis, re¯ecting the slow progression rate of hepatitis C. The incidence of HCV-related cirrhosis (®rst complication of HCV infection) rose until 2005 but declined thereafter, even if the annual incidence of new HCV infections was increased by two-thirds to 1238 (Fig. 3) . The decline occurs because of the decrease in new infections since 1990 (after mandatory screening of blood products) and the ageing and dying (due to all causes) of the cohort of currently infected patients. This result remained stable even with the variations to base-case estimates used in the simulation model (Table 3) .
Effect of antiviral treatment
Antiviral therapy would reduce annual HCV-related mortality by about 5%, measured as the annual reductions of death of HCV-related chronic liver disease or HCC in 15±25 years. This small reduction in annual mortality is mainly caused by the small fraction of HCV infected subjects diagnosed today (14%) and a response rate of 40%.
Costs
Direct costs
Based on our simulation of the HCV epidemic (see earlier) and the annual cost per disease state (cf. Table  4) , we estimate the total direct costs of HCV-related diseases in Switzerland to be US$16.1 million (i.e. US$2.3 million/million inhabitants) for 1998. To be conservative, we only estimated future costs for HCVinfected subjects prevalent in 1998. The yearly (undiscounted) costs will double until 2020, reaching a maximum of US$32.9 million in 2020 ( Table 8 ). The cumulated (discounted) costs of the entire cohort of HCV-infected subjects will sum up to US$32.8 million by 2025.
Indirect costs
For the modelled cohort of 77 595 HCV-infected subjects prevalent in 1998 in Switzerland, our analysis estimates a loss of 479 500 years of future life due to complications of HCV infection. Restricting the analysis to those between 20 and 60 years of age (as years of productivity) results in a loss of 94 800 years. For 1998, our model estimates a loss of 699 years due to disability in individuals aged 20±60 years, with a loss of productivity of US$25.9 million.
Discussion
The mandatory reporting of diagnostic tests positive for HCV markers to the BAG combined with detailed clinical information from primary care physicians creates a unique epidemiological data set on HCV infection in Switzerland. The data collected by the BAG allow the differentiation of acute from chronic infections and permit determination of the age distribution of infected subjects. This database, therefore, enabled a comprehensive computer simulation, going further than previous approaches [13, 14] . The results of our modelling of the HCV epidemic in Switzerland can be summarized as follows.
1. The anti-HCV prevalence in the Swiss population was estimated to be 1.25±1.75% using a validated model of the natural history of HCV infection and Future complications based on the hepatitis C virus (HCV) cohort prevalent in 1998. HCC, incidence of HCV-related hepatocellular carcinoma; OLT, orthotopic liver transplantation for HCV-related endstage liver disease; CIR, incidence of HCV-related liver cirrhosis; DCIR, incidence of decompensated HCV-related liver cirrhosis; DLD, death of HCV-related chronic liver disease. Future incidence of hepatitis C virus (HCV)-related cirrhosis, based on the HCV cohort prevalent in 1998 and different incidence rates for new HCV infections (annual HCV infections, 746±1238).
back-calculation of observed events (i.e. incidence of HCV-related HCC, death from HCV-related liver disease, OLT for HCV-related end-stage liver disease). This is slightly higher than BAG estimates (i.e. up to 1.0%) because of differences in methodology, i.e. modelling and back-calculation of observed events versus projection from prevalences in highly selected populations. 2. The model predicts increasing HCV-related disease burden for the next 20 years, with HCV-related morbidity and mortality almost doubling by approximately 2020. These predictions are similar to those made by the US Centers for Disease Control and Prevention [47] , and model calculations performed by Wong et al. [14] and Deuf®c et al. [13] for the USA and France, respectively. Because of the decrease in new HCV infections since 1990 due to screening of blood donors, the annual incidence of HCV-related cirrhosis in Switzerland is predicted to rise up to 2005 and decline afterwards, indicating that the epidemic might decrease. 3. The model also predicts that HCV-related morbidity and mortality will lead to rising societal costs over the next 20 years, reaching a maximum in 2020. Thus, annual (undiscounted) direct costs for treating complications of HCV-related liver disease may double by 2020, reaching almost US$32.9 million per year. The estimated HCV-related direct costs in 1998 of US$16.1 million are, however, relatively small compared with the US$801 million direct costs attributable to coronary heart disease in Switzerland [56] (in¯ated from 1993 to 1998 health care dollars [46] ).
As with any modelling approach, our analysis required making assumptions in the absence of clinical and epidemiological data. Thus, our estimate of the prevalence of HCV infection in Switzerland depends on the likelihood of developing HCV complications (e.g. death from HCV-related HCC or liver disease) and the availability of OLT for HCV-related end-stage liver disease. Even with a lower assumed number of HCVrelated complications in 1998, however, our analysis would suggest that the incidence of HCV-related complications would still increase during the next 20 years, albeit with a lower annual burden.
Our simulation may have underestimated the future disease burden for the following reasons: we assumed that HCV-infected patients exhibiting persistently normal transaminases do not develop progressive liver disease. While this assumption seems to hold true for the majority of this subgroup of patients [57] , the potential of a minority eventually progressing to more advanced disease states is not entirely excluded. Because patients with persistently normal transaminases account for 30±40% of all chronically HCV-infected subjects [21] , even a minority progressing to advanced disease states may signi®cantly increase future HCVrelated disease burden and costs. HCV, hepatitis C virus. Finally, we considered the effect of antiviral therapies (i.e. standard interferon/ribavirin combination) on patients with known disease [48, 49, 61] . By obviating progression to advanced disease states in a proportion of patients, these therapies may reduce disease burden in the future. Nevertheless, only a small percentage (14%) of prevalent HCV-infected patients are diagnosed and a signi®cant proportion of these were diagnosed with established cirrhosis only partly amenable to antiviral therapy. Therefore, even with the bene®t of antiviral treatment, the future disease burden would only be decreased by 5% in the absence of systematic screening for HCV. New therapies such as pegylated interferon in combination with ribavirin that have overall sustained response rates up to 54% [62] will have the same limitations (small percentage of infected patients known, diagnosis with already established cirrhosis) as standard interferon/ribavirin, and therefore will only have a limited effect on the future disease burden.
Systematic screening for chronic hepatitis C has been evaluated neither clinically nor in relation to its costeffectiveness and is not performed routinely in Switzerland. Nevertheless, screening for hepatitis C could be cost-effective and is recommended for certain risk groups (i.e. patients with transfusion of blood products before 1990, former injecting drug users, etc.) [47, 63] . To answer the question on the bene®t of a large-scale screening programme for hepatitis C, further research is needed.
patients for HCC [24] . This survey probably overestimates screening practice because it only includes AASLD members. In Switzerland, routine screening of cirrhotic patients for HCC by sonography and alphafetoprotein is common, so we assumed that 50±70% (base-case, 60%) of patients with known HCV-associated cirrhosis are screened routinely. However, 30± 56% (base-case, 40%) of patients with HCC have silent, unrecognized cirrhosis at the time of HCC diagnosis and will therefore not be recruited in a screening procedure [25, 26] . In a screened cirrhotic population, about 80% (66±100%) of all HCC will present as a small, single lesion with a diameter < 5 cm at diagnosis (50±75% as a tumour < 3 cm) that is possibly amenable to resection [27] . Not all of these patients, however, undergo surgery because only 29±54% (base-case, 40%) are ultimately resected. The high portion of undiagnosed cirrhosis and the low resection rate may be the main limitations of successful screening programmes for HCC in cirrhotic patients. Because of these considerations, we assumed that about 10% of all HCC will be resected. This is consistent with prospective and retrospective (possibly biased to more intensive treating) studies showing a range of surgical treatment from 6% (partial hepatectomy) [28] to 11±20% (partial hepatectomy and OLT) [29, 30] .
One-year survival after partial hepatectomy for HCC ranges from 68 to 79%, and 5-year survival ranges from 37 to 38.6% [30±34]. The biggest series with 412 patients and partial hepatectomy was reported recently by Fong et al. [31] , with a reported 1-year and 5-year survival for patients with cirrhosis of 77 and 37%, respectively (base-case: 1-year survival, 75%; 5-year survival, 38%).
OLT and HCC
In 1996, 327 patients died of HCC in Switzerland (BFS, unpublished data 1999). As reported in other countries, about 35% of all HCC (range, 98±132 HCC) are estimated to be related to HCV in Switzerland [35] . Based on an evaluation of 62 consecutive OLTs at the University Hospital Zu È rich (E. L. Renner, unpublished data 2000), two HCC were related to HCV (3.2%). Taking the same rate for all OLTs in Switzerland (67 OLTs in 1996) [36] , we assumed 2.2 OLTs for HCVassociated HCC in 1996. Collectively, this led us to assume a probability of 1.9% for a HCV-related HCC to undergo OLT.
The literature shows considerable overall variability in the survival after OLT for HCC as post-operative tumour recurrence correlates with tumour size and with the number of lesions. In well-selected patients with small tumours < 5 cm, the perioperative mortality and 5-year survival are 6 and 57±75%, respectively [37±39].
Advanced HCC
The 1-year survival of patients with advanced HCC (tumour exceeding 5 cm in diameter, more than three nodules, or invasion of blood vessels) is about 20% [28, 29, 40] .
Transition probabilities from HCC
To adjust mortality rates (r) to probabilities (P), we applied the declining exponential approximation of life expectancy (`Deale') [41] . Thus, mortality rates (r) were converted to annual transition probabilities (P) using the expression P e ±rt [42] , where t 1 year (Table 3) . Age-speci®c mortality data (from all other causes) were obtained from of®cial Swiss mortality tables [43] .
